T
Timothy M. Nywening
Researcher at Washington University in St. Louis
Publications - 18
Citations - 2891
Timothy M. Nywening is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Colorectal cancer & Tumor microenvironment. The author has an hindex of 11, co-authored 15 publications receiving 2083 citations.
Papers
More filters
Journal ArticleDOI
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu,Brett L. Knolhoff,Melissa A. Meyer,Timothy M. Nywening,Brian L. West,Jingqin Luo,Andrea Wang-Gillam,S. Peter Goedegebuure,David C. Linehan,David G. DeNardo +9 more
TL;DR: It is demonstrated in a mouse model of pancreatic ductal adenocarcinoma (PDAC) that inhibiting signaling by the myeloid growth factor receptor CSF1R can functionally reprogram macrophage responses that enhance antigen presentation and productive antitumor T-cell responses.
Journal ArticleDOI
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang,Samarth Hegde,Brett L. Knolhoff,Yu Zhu,John M. Herndon,Melissa A. Meyer,Timothy M. Nywening,William G. Hawkins,Irina M. Shapiro,David T. Weaver,Jonathan A. Pachter,Andrea Wang-Gillam,David G. DeNardo +12 more
TL;DR: It is suggested that FAK inhibition increases immune surveillance by overcoming the fibrotic and immunosuppressive PDAC TME and renders tumors responsive to immunotherapy.
Journal ArticleDOI
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening,Andrea Wang-Gillam,Dominic E. Sanford,Brian A. Belt,Roheena Z. Panni,Brian Cusworth,Adetunji T. Toriola,Rebecca Nieman,Lori A. Worley,Motoyo Yano,Kathryn J. Fowler,A. Craig Lockhart,Rama Suresh,Benjamin R. Tan,Kian-Huat Lim,Ryan C. Fields,Steven M. Strasberg,William G. Hawkins,David G. DeNardo,S. Peter Goedegebuure,David C. Linehan +20 more
TL;DR: This trial aimed to establish the safety, tolerability, and recommended phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combination with FOLFIRINOX chemotherapy (oxaliplatin and irinotecan plus leucovorin and fluorouracil) and analysed the primary outcome by intention to treat.
Journal ArticleDOI
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
Timothy M. Nywening,Brian A. Belt,Darren R. Cullinan,Roheena Z. Panni,Booyeon J. Han,Dominic E. Sanford,Ryan C Jacobs,Jian Ye,Ankit A Patel,William E. Gillanders,Ryan C. Fields,David G. DeNardo,William G. Hawkins,Peter S. Goedegebuure,David C. Linehan +14 more
TL;DR: CCR2 and CXCR2 combined blockade reduces total tumour-infiltrating myeloids, promoting a more robust antitumour immune response in PDAC compared with either strategy alone.
Journal ArticleDOI
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.
Melissa A. Meyer,John M. Baer,Brett L. Knolhoff,Timothy M. Nywening,Roheena Z. Panni,Xinming Su,Katherine N. Weilbaecher,William G. Hawkins,Cynthia X. Ma,Ryan C. Fields,David C. Linehan,Grant A. Challen,Roberta Faccio,Rebecca Aft,Rebecca Aft,David G. DeNardo +15 more
TL;DR: It is shown that certain tumors inhibit anti-tumor immunity by stopping the production of conventional dendritic cells (cDCs) in the bone marrow, therefore depleting the pool of cDCs available to present antigen to CD8+ T cells.